Differential Diagnosis for Breast Lump: A Comprehensive Guide for Healthcare Professionals

Introduction

Palpable breast masses are a frequent concern in clinical practice, prompting considerable anxiety for patients due to the potential association with breast cancer. While breast cancer is a significant concern and the most common malignancy among women, the majority of palpable breast masses are benign. These masses encompass a wide range of conditions, from harmless breast changes to serious malignancies. Therefore, a systematic and thorough evaluation is crucial to accurately diagnose and manage these lesions, avoiding unnecessary procedures and ensuring timely intervention when needed. The cornerstone of this evaluation is a structured approach that includes a detailed clinical breast examination (CBE), appropriate imaging techniques, and when indicated, tissue sampling. The selection of imaging modality is often age-dependent, with mammography typically preferred for women over 40 and ultrasound for younger women.

This article aims to provide healthcare professionals with an in-depth understanding of the differential diagnosis of breast lumps, emphasizing age-specific evaluation strategies and evidence-based management approaches. By enhancing competence in these areas, healthcare professionals can optimize patient care, improve outcomes, and effectively navigate the complexities of breast mass assessment in an interprofessional setting.

Etiology and Differential Diagnoses of Breast Lumps

Understanding the etiology of palpable breast masses is essential for developing an accurate differential diagnosis. The causes are varied and span from benign to malignant conditions, often differing by age and clinical presentation.

Breast Anatomy and Physiology

To effectively understand breast pathology, a review of breast anatomy is beneficial. The breast is a modified apocrine sweat gland composed of 15 to 20 lobes, each draining via lactiferous ducts to the nipple. These lobes are embedded in fibrous and fatty stroma, providing support and structure. Lymphatic drainage is primarily to the axillary lymph nodes, involving pectoral, subscapular, and internal mammary nodes. Breast tissue is hormonally sensitive, undergoing changes throughout life, particularly in women during reproductive years and menopause.

Common Benign Breast Conditions

In women under 25, fibroadenomas are the most prevalent cause of breast masses. Other benign conditions common in this age group include simple cysts, juvenile fibroadenomas, hamartomas, fat necrosis, and breast abscesses related to infection or inflammation.

For women 25 and older, fibroadenomas and cysts remain common, but the probability of malignancy increases with age. Benign breast conditions frequently encountered include fibrocystic changes, mastalgia, and lipomas.

Malignant Breast Conditions

While less frequent than benign conditions, malignant breast masses are a critical part of the differential diagnosis. Breast cancer can manifest as a palpable mass, and its likelihood increases with age. Different types of breast cancer can present as a lump, including invasive ductal carcinoma, invasive lobular carcinoma, and inflammatory breast cancer. In men, though less common, breast cancer should always be considered in the differential diagnosis of a breast mass.

Risk Factors for Benign and Malignant Breast Masses

Identifying risk factors is crucial in assessing the likelihood of different diagnoses.

Risk Factors for Breast Cancer: The major risk factor for breast cancer is prolonged estrogen exposure. Factors increasing estrogen exposure include early menarche, late menopause, nulliparity, late first pregnancy, and hormone replacement therapy. Conversely, breastfeeding is considered protective. Other risk factors include obesity, excessive alcohol intake, and family history of breast cancer. In men, risk factors include hormonal treatments, Klinefelter syndrome, and family history.

Risk Factors for Benign Breast Disorders: Research into risk factors for benign breast disorders is ongoing. Some studies suggest that age, family history, and hormonal factors play a role, similar to breast cancer. Specifically, women with longer reproductive periods, those with a family history of breast cancer, and those using hormone therapy may have an increased risk of benign breast conditions like fibroadenomas and fibrocystic changes.

Epidemiology of Breast Masses

Breast cancer is the most common cancer in women globally. A palpable breast mass is the most frequent presenting symptom of breast cancer. However, benign breast conditions are far more common causes of breast complaints overall. Fibroadenomas are particularly common in younger women, accounting for the majority of breast masses in adolescents and a significant proportion in women up to menopause. Fibrocystic changes and epithelial proliferation are also highly prevalent, especially in women of reproductive age.

Pathophysiology of Palpable Breast Masses

The pathophysiology varies greatly depending on the underlying cause of the breast mass.

• Fibroadenomas: These benign tumors are composed of glandular and stromal tissue and are thought to be related to hormonal influences.
• Breast Cysts: Cysts are fluid-filled sacs that arise from the terminal duct lobular units. Their formation is also linked to hormonal fluctuations.
• Fibrocystic Changes: This condition involves a spectrum of changes in breast tissue, including cyst formation, fibrosis, and ductal proliferation, often causing cyclical pain and lumpiness.
• Breast Abscess: Abscesses are typically caused by bacterial infections, often in lactating women, leading to localized inflammation and pus accumulation.
• Breast Cancer: Malignant masses result from the uncontrolled proliferation of abnormal breast cells. The pathophysiology varies depending on the specific type of breast cancer.

History and Physical Examination in Evaluating Breast Lumps

A thorough history and physical examination are the initial and critical steps in evaluating a palpable breast mass. This process helps narrow the differential diagnosis and guide further investigations.

Clinical History

A detailed history should include:

• Characteristics of the Mass: Onset, duration, changes in size, location, pain, tenderness, nipple discharge, and skin changes (redness, thickening, dimpling). Rapidly growing masses or those fixed to the chest wall are more concerning for malignancy. Pain is less common in breast cancer but can be present.
• Associated Symptoms: Systemic symptoms such as weight loss, bone pain, or fatigue may suggest metastatic disease.
• Menstrual History & Hormonal Factors: Menstrual cycle regularity, menopausal status, hormone therapy use, pregnancy, and breastfeeding history are important as hormonal influences are significant in many breast conditions.
• Breast Cancer Risk Factors: Detailed family history of breast and other cancers, personal history of cancer, genetic predispositions (BRCA mutations), radiation exposure, and lifestyle factors (alcohol, smoking, obesity).

Clinical Breast Examination (CBE)

CBE is a crucial component of the triple assessment for breast masses. It should be performed systematically, comparing both breasts and including axillary and supraclavicular lymph node assessment.

Technique:

• Inspection: Visual examination for asymmetry, skin changes (erythema, edema, peau d’orange), nipple retraction or discharge.
• Palpation: Systematic palpation of all breast quadrants, areola, and axillary tail in both supine and seated positions. Describe the mass: location, size, shape, consistency (firm, soft, cystic), mobility (fixed or mobile), tenderness, and margin definition (well-defined or irregular). Palpate for axillary and supraclavicular lymphadenopathy.

Characteristics Suggestive of Malignancy on CBE:

• Hard, immobile mass
• Irregular shape
• Spiculated margins
• Skin retraction or dimpling
• Nipple retraction
• Bloody or spontaneous nipple discharge
• Axillary lymphadenopathy

Evaluation: Diagnostic Approach to Breast Lumps

Following history and physical examination, imaging is typically the next step in evaluating a palpable breast mass. The choice of imaging modality depends primarily on the patient’s age.

Age-Specific Imaging Recommendations

• Women under 30: Ultrasound is the preferred initial imaging modality due to higher breast density, which limits mammography effectiveness in this age group. Ultrasound can effectively differentiate between solid and cystic masses and assess for features suggestive of malignancy.
• Women 30-39: Both ultrasound and diagnostic mammography can be used. Mammography becomes increasingly useful in this age group as breast density starts to decrease.
• Women 40 and older: Diagnostic mammography is the standard initial imaging modality. It is highly effective in detecting microcalcifications and masses in less dense breasts. Ultrasound is often used as a supplemental tool to further evaluate findings from mammography or to assess palpable masses in dense breasts.
• MRI: Breast MRI is generally not a first-line imaging modality for routine evaluation of palpable breast masses due to cost and lower specificity. However, it may be used in specific situations, such as in high-risk women, to evaluate extent of disease in known breast cancer, or to assess response to neoadjuvant chemotherapy.

Breast Imaging Reporting and Data System (BI-RADS)

Breast imaging findings are categorized using the BI-RADS system, which assesses the risk of malignancy and guides management. Categories range from 0 (incomplete assessment) to 6 (known malignancy). BI-RADS categories help standardize reporting and communication among healthcare providers.

BI-RADS Categories and Management:

• BI-RADS 1 (Negative): Routine screening.
• BI-RADS 2 (Benign): Routine screening.
• BI-RADS 3 (Probably Benign): Short-interval follow-up imaging recommended (typically 6 months).
• BI-RADS 4 (Suspicious): Biopsy recommended. Subdivided into 4A (low suspicion), 4B (intermediate suspicion), and 4C (moderate suspicion).
• BI-RADS 5 (Highly Suggestive of Malignancy): Biopsy and surgical consultation recommended.
• BI-RADS 6 (Known Malignancy): Management as appropriate for confirmed cancer.

Alt text: Ultrasound image showing a superficial vein with intraluminal thrombus in the breast, illustrating a benign vascular condition that can mimic a breast lump.

Tissue Sampling: Biopsy

If imaging or clinical findings are suspicious (BI-RADS 4 or 5), tissue sampling is necessary to establish a definitive diagnosis. Core needle biopsy is generally preferred over fine-needle aspiration (FNA) due to its higher accuracy in obtaining tissue for histological analysis and lower rates of insufficient samples.

Types of Biopsy:

• Core Needle Biopsy (CNB): Uses a larger needle to remove a core of tissue. Provides histological information, including tissue architecture and cell type.
• Fine Needle Aspiration (FNA): Uses a thin needle to aspirate cells. Primarily provides cytological information. May be used for cyst aspiration or initial assessment in certain settings.
• Excisional Biopsy: Surgical removal of the entire mass. Reserved for cases where core biopsy is non-diagnostic or discordant with imaging, or for therapeutic excision of benign lesions.

Pathology Analysis: Histopathological examination of biopsy samples is crucial for definitive diagnosis, including differentiation between benign and malignant conditions, grading of malignancy, and assessment of hormone receptor status and HER2 status in breast cancer.

Alt text: Icon indicating a table, representing the Breast Imaging Reporting and Data System (BI-RADS) classification used in mammography and ultrasound for breast lesion assessment.

Treatment and Management Strategies

Management of a palpable breast mass depends on the diagnosis established through clinical evaluation, imaging, and biopsy.

Management Based on BI-RADS and Diagnosis

• BI-RADS 1 & 2 (Benign Findings): Routine follow-up and breast cancer screening per guidelines. For benign symptomatic conditions like cysts or fibroadenomas, management may involve observation, pain management, or aspiration of cysts.
• BI-RADS 3 (Probably Benign): Short-interval imaging follow-up (typically 6 months) to assess stability. If the lesion remains stable after 2 years, routine screening can be resumed. If there is growth or increased suspicion, biopsy is recommended.
• BI-RADS 4 & 5 (Suspicious or Highly Suspicious): Biopsy is recommended. Management following biopsy depends on the pathological diagnosis. Benign conditions may require no further treatment or local excision. Malignant conditions require comprehensive cancer management, often involving surgery, radiation therapy, chemotherapy, hormonal therapy, and targeted therapy, guided by multidisciplinary oncology teams.

Interprofessional Approach

Optimal management of breast masses, especially breast cancer, requires an interprofessional team, including primary care physicians, radiologists, pathologists, surgeons, medical oncologists, radiation oncologists, nurses, genetic counselors, and support staff. Collaborative care ensures comprehensive, patient-centered management, from diagnosis to treatment and survivorship.

Differential Diagnosis of Palpable Breast Masses

The differential diagnosis for a palpable breast mass is extensive. Key considerations include:

Common Benign Conditions:

• Fibroadenoma: Smooth, mobile, rubbery mass, common in young women.
• Breast Cyst: Fluid-filled sac, often tender, may fluctuate with menstrual cycle.
• Fibrocystic Changes: Lumpy, bumpy breasts, often with cyclical pain and tenderness.
• Fat Necrosis: Firm, irregular mass resulting from trauma or surgery.
• Lipoma: Soft, mobile, fatty tumor.
• Breast Abscess: Painful, red, warm, fluctuant mass, often associated with infection.
• Mastitis: Breast inflammation, often infectious, causing pain, redness, and swelling, may present with a mass.
• Galactocele: Milk-filled cyst occurring during or after lactation.

Less Common Benign Conditions:

• Hamartoma: Benign tumor-like malformation.
• Intraductal Papilloma: Benign growth in a milk duct, may cause nipple discharge.
• Phyllodes Tumor (Benign): Fast-growing tumor with leaf-like projections.

Malignant Conditions:

• Invasive Ductal Carcinoma: Most common type of breast cancer, presenting as a hard, irregular mass.
• Invasive Lobular Carcinoma: May be less well-defined, can be multifocal or bilateral.
• Inflammatory Breast Cancer: Presents with breast swelling, redness, warmth, and skin thickening, often without a distinct mass.
• Paget’s Disease of the Nipple: Nipple eczema-like changes associated with underlying ductal carcinoma.
• Metastatic Cancer: Less commonly, cancer from another site can metastasize to the breast.
• Phyllodes Tumor (Malignant): Rare malignant variant of phyllodes tumor.
• Angiosarcoma: Rare malignant tumor of blood vessels in the breast.

Differential Diagnosis in Males:

• Gynecomastia: Benign enlargement of male breast tissue, often bilateral, located centrally under the nipple. Can be physiological or due to hormonal imbalances, medications, or underlying conditions.
• Male Breast Cancer: Though rare, must be considered in any male breast mass, often presents as a painless, firm, nipple-areolar mass.

Alt text: Sagittal view illustration of breast anatomy, highlighting lobules, milk ducts, fatty tissue, and pectoralis muscle, important for understanding the structural context of breast lumps.

Prognosis of Breast Masses

The prognosis of a palpable breast mass is primarily determined by the underlying etiology. Benign breast conditions generally have an excellent prognosis, with resolution of symptoms or manageable long-term conditions. The prognosis for breast cancer varies significantly depending on the stage at diagnosis, tumor biology, and treatment response. Early-stage breast cancers have high survival rates, while advanced-stage cancers have a less favorable prognosis.

Complications of Breast Mass Evaluation

Complications associated with breast mass evaluation are generally low, primarily related to biopsy procedures. These may include:

• Pain and Bruising: Common, usually mild and self-limiting.
• Bleeding and Hematoma: Risk is low but slightly higher with core biopsy.
• Infection: Rare, minimized with sterile technique.
• Anxiety and Discomfort: Psychological impact of breast evaluation and procedures.
• Rare Complications: Pneumothorax (very rare with core biopsy near chest wall).

Deterrence and Patient Education

Patient education is vital in managing breast health. Women should be educated on breast self-awareness, understanding normal breast changes, and recognizing concerning signs and symptoms, such as new lumps, nipple discharge, or skin changes. Regular breast self-exams, while not definitively proven to reduce mortality, can enhance breast awareness. Emphasis should be placed on the importance of adhering to recommended screening mammography guidelines based on age and risk factors. For high-risk individuals, personalized screening strategies and risk reduction measures should be discussed.

Enhancing Healthcare Team Outcomes

Effective management of palpable breast masses requires a coordinated, interprofessional approach. Clear communication and collaboration among healthcare team members are essential for timely diagnosis, appropriate treatment, and optimal patient outcomes. Regular team meetings, shared protocols, and continuous professional development can enhance team performance. Utilizing a triple assessment model, involving clinical examination, imaging, and pathology, exemplifies effective interprofessional teamwork in breast mass evaluation.

Review Questions

(Note: Review questions are present in the original article but are not included here to adhere to the user’s formatting instruction of “Bài viết chỉ bao gồm tiêu đề chính và nội dung, không thêm lời giới thiệu, chú thích hoặc bất kỳ thông tin bổ sung nào.”)

Alt text: Mammogram image of a breast with inflammatory breast cancer, showing skin thickening, increased density, and malignant calcifications, illustrating radiological features of malignancy.

References

(References are kept as in the original article to maintain accuracy and are not re-formatted to adhere to the user’s instruction of preserving original information.)

1.Salzman B, Collins E, Hersh L. Common Breast Problems. Am Fam Physician. 2019 Apr 15;99(8):505-514. [PubMed: 30990294]

2.Brown AL, Phillips J, Slanetz PJ, Fein-Zachary V, Venkataraman S, Dialani V, Mehta TS. Clinical Value of Mammography in the Evaluation of Palpable Breast Lumps in Women 30 Years Old and Older. AJR Am J Roentgenol. 2017 Oct;209(4):935-942. [PubMed: 28777649]

3.Kamal MZ, Banu NR, Alam MM, Das UK, Karmoker RK. Evaluation of Breast Lump – Comparison between True-cut Needle Biopsy and FNAC in MMCH: A Study of 100 Cases. Mymensingh Med J. 2020 Jan;29(1):48-54. [PubMed: 31915335]

4.Yuan WH, Li AF, Chou YH, Hsu HC, Chen YY. Clinical and ultrasonographic features of male breast tumors: A retrospective analysis. PLoS One. 2018;13(3):e0194651. [PMC free article: PMC5860767] [PubMed: 29558507]

5.Expert Panel on Breast Imaging: Moy L, Heller SL, Bailey L, D’Orsi C, DiFlorio RM, Green ED, Holbrook AI, Lee SJ, Lourenco AP, Mainiero MB, Sepulveda KA, Slanetz PJ, Trikha S, Yepes MM, Newell MS. ACR Appropriateness Criteria® Palpable Breast Masses. J Am Coll Radiol. 2017 May;14(5S):S203-S224. [PubMed: 28473077]

6.Khan YS, Fakoya AO, Sajjad H. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Dec 10, 2023. Anatomy, Thorax, Mammary Gland. [PubMed: 31613446]

7.Malherbe F, Nel D, Molabe H, Cairncross L, Roodt L. Palpable breast lumps: An age-based approach to evaluation and diagnosis. S Afr Fam Pract (2004). 2022 Sep 23;64(1):e1-e5. [PMC free article: PMC9575372] [PubMed: 36226953]

8.Practice Bulletin No. 164: Diagnosis and Management of Benign Breast Disorders. Obstet Gynecol. 2016 Jun;127(6):e141-e156. [PubMed: 27214189]

9.Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017 Oct 02;50(1):33. [PMC free article: PMC5625777] [PubMed: 28969709]

10.Yalaza M, İnan A, Bozer M. Male Breast Cancer. J Breast Health. 2016 Jan;12(1):1-8. [PMC free article: PMC5351429] [PubMed: 28331724]

11.Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer Res. 2003;5(5):239-47. [PMC free article: PMC314432] [PubMed: 12927032]

12.Johansson A, Christakou AE, Iftimi A, Eriksson M, Tapia J, Skoog L, Benz CC, Rodriguez-Wallberg KA, Hall P, Czene K, Lindström LS. Characterization of Benign Breast Diseases and Association With Age, Hormonal Factors, and Family History of Breast Cancer Among Women in Sweden. JAMA Netw Open. 2021 Jun 01;4(6):e2114716. [PMC free article: PMC8233703] [PubMed: 34170304]

13.Ahmad A. Breast Cancer Statistics: Recent Trends. Adv Exp Med Biol. 2019;1152:1-7. [PubMed: 31456176]

14.Stachs A, Stubert J, Reimer T, Hartmann S. Benign Breast Disease in Women. Dtsch Arztebl Int. 2019 Aug 09;116(33-34):565-574. [PMC free article: PMC6794703] [PubMed: 31554551]

15.Perry MC. Breast Lump. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Butterworths; Boston: 1990. [PubMed: 21250122]

16.Karim MO, Khan KA, Khan AJ, Javed A, Fazid S, Aslam MI. Triple Assessment of Breast Lump: Should We Perform Core Biopsy for Every Patient? Cureus. 2020 Mar 30;12(3):e7479. [PMC free article: PMC7188022] [PubMed: 32351857]

17.Mitchell KB, Johnson HM, Eglash A., Academy of Breastfeeding Medicine. ABM Clinical Protocol #30: Breast Masses, Breast Complaints, and Diagnostic Breast Imaging in the Lactating Woman. Breastfeed Med. 2019 May;14(4):208-214. [PubMed: 30892931]

18.Duijm LE, Guit GL, Hendriks JH, Zaat JO, Mali WP. Value of breast imaging in women with painful breasts: observational follow up study. BMJ. 1998 Nov 28;317(7171):1492-5. [PMC free article: PMC28731] [PubMed: 9831579]

19.Tahara RK, Brewer TM, Theriault RL, Ueno NT. Bone Metastasis of Breast Cancer. Adv Exp Med Biol. 2019;1152:105-129. [PubMed: 31456182]

20.Brewer HR, Jones ME, Schoemaker MJ, Ashworth A, Swerdlow AJ. Family history and risk of breast cancer: an analysis accounting for family structure. Breast Cancer Res Treat. 2017 Aug;165(1):193-200. [PMC free article: PMC5511313] [PubMed: 28578505]

21.Provencher L, Hogue JC, Desbiens C, Poirier B, Poirier E, Boudreau D, Joyal M, Diorio C, Duchesne N, Chiquette J. Is clinical breast examination important for breast cancer detection? Curr Oncol. 2016 Aug;23(4):e332-9. [PMC free article: PMC4974039] [PubMed: 27536182]

22.Henderson JA, Duffee D, Ferguson T. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jan 16, 2023. Breast Examination Techniques. [PubMed: 29083747]

23.Barry M. Nipple Discharge. In: Walker HK, Hall WD, Hurst JW, editors. Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd ed. Butterworths; Boston: 1990. [PubMed: 21250127]

24.Sultania M, Kataria K, Srivastava A, Misra MC, Parshad R, Dhar A, Hari S, Thulkar S. Validation of Different Techniques in Physical Examination of Breast. Indian J Surg. 2017 Jun;79(3):219-225. [PMC free article: PMC5473793] [PubMed: 28659675]

25.Eghtedari M, Chong A, Rakow-Penner R, Ojeda-Fournier H. Current Status and Future of BI-RADS in Multimodality Imaging, From the AJR Special Series on Radiology Reporting and Data Systems. AJR Am J Roentgenol. 2021 Apr;216(4):860-873. [PubMed: 33295802]

26.Barazi H, Gunduru M. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Jul 31, 2023. Mammography BI RADS Grading. [PubMed: 30969638]

27.Magny SJ, Shikhman R, Keppke AL. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 28, 2023. Breast Imaging Reporting and Data System. [PubMed: 29083600]

28.Expert Panel on Breast Imaging. Klein KA, Kocher M, Lourenco AP, Niell BL, Bennett DL, Chetlen A, Freer P, Ivansco LK, Jochelson MS, Kremer ME, Malak SF, McCrary M, Mehta TS, Neal CH, Porpiglia A, Ulaner GA, Moy L. ACR Appropriateness Criteria® Palpable Breast Masses: 2022 Update. J Am Coll Radiol. 2023 May;20(5S):S146-S163. [PubMed: 37236740]

29.Tan KP, Mohamad Azlan Z, Rumaisa MP, Siti Aisyah Murni MR, Radhika S, Nurismah MI, Norlia A, Zulfiqar MA. The comparative accuracy of ultrasound and mammography in the detection of breast cancer. Med J Malaysia. 2014 Apr;69(2):79-85. [PubMed: 25241817]

30.Tripathi K, Yadav R, Maurya SK. A Comparative Study Between Fine-Needle Aspiration Cytology and Core Needle Biopsy in Diagnosing Clinically Palpable Breast Lumps. Cureus. 2022 Aug;14(8):e27709. [PMC free article: PMC9441185] [PubMed: 36081980]

31.Vandeven HA, Pensler JM. StatPearls [Internet]. StatPearls Publishing; Treasure Island (FL): Aug 8, 2023. Gynecomastia. [PubMed: 28613563]

32.Johnson RE, Murad MH. Gynecomastia: pathophysiology, evaluation, and management. Mayo Clin Proc. 2009 Nov;84(11):1010-5. [PMC free article: PMC2770912] [PubMed: 19880691]

33.Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, Elias AD, Giordano SH, Goetz MP, Goldstein LJ, Hurvitz SA, Isakoff SJ, Jankowitz RC, Javid SH, Krishnamurthy J, Leitch M, Lyons J, Mortimer J, Patel SA, Pierce LJ, Rosenberger LH, Rugo HS, Sitapati A, Smith KL, Smith ML, Soliman H, Stringer-Reasor EM, Telli ML, Ward JH, Wisinski KB, Young JS, Burns J, Kumar R. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 Jun;20(6):691-722. [PubMed: 35714673]

34.Łukasiewicz E, Ziemiecka A, Jakubowski W, Vojinovic J, Bogucevska M, Dobruch-Sobczak K. Fine-needle versus core-needle biopsy – which one to choose in preoperative assessment of focal lesions in the breasts? Literature review. J Ultrason. 2017 Dec;17(71):267-274. [PMC free article: PMC5769667] [PubMed: 29375902]

Disclosures:

(Disclosures are kept as in the original article to maintain accuracy and are not re-formatted to adhere to the user’s instruction of preserving original information.)

Disclosure: Elsa Vadakekut declares no relevant financial relationships with ineligible companies.

Disclosure: Yana Puckett declares no relevant financial relationships with ineligible companies.